Prestige Biopharma Outlines Phase 2a Clinical Development Roadmap for Pancreatic Cancer Therapy PBP1510

ESMO 2026 Abstract Submission Completed Preparing Presentation Based on Efficacy and Safety Data

Prestige Biopharma announced on June 1 that it is accelerating the next phase of the clinical development roadmap for its pancreatic cancer therapeutic antibody, PBP1510, based on accumulated clinical data.

The company has recently completed the submission of an abstract to the European Society for Medical Oncology (ESMO) 2026 Annual Congress and has begun preparations to present its future clinical development strategy to the global oncology community based on efficacy and safety data.

The abstract submitted to ESMO 2026, for which submissions closed on May 12, includes key efficacy and safety findings from PBP1510. The presentation will be led by Dr. King, a medical oncologist at the Northwell Health Cancer Institute in the United States and the principal investigator of the clinical study, drawing significant attention from the global oncology community.

Previously, at ESMO 2025, Prestige Biopharma presented the PAUF-targeting mechanism of PBP1510 (Ulenistamab) along with initial clinical development results. Based on data from 32 treated patients, the company highlighted the favorable safety profile observed with both 30 mg/kg monotherapy and 10 mg/kg combination therapy, with no dose-limiting toxicities (DLTs) reported.

At ESMO 2026, Prestige Biopharma plans to further refine its global development strategy and Phase 2a clinical trial design based on the efficacy and safety data accumulated to date. Drawing on ongoing Phase 1 trial results, the company is evaluating the optimal dosing regimen and treatment strategy, with the goal of initiating a Phase 2a study in the second half of this year.

In preparation for ESMO 2026, the company is also accelerating the formation of an Advisory Board to discuss the next stage of clinical development for PBP1510. Presentation materials will include clinical data accumulated through May 15, 2026, as well as the proposed Phase 2a study design. Based on these findings, Prestige Biopharma plans to engage with Dr. King, future global key opinion leaders (KOLs), and potential principal investigators (PIs) to discuss target patient populations, study endpoints, dosing strategies, and other aspects of future clinical development.

Development of PAUF-based diagnostic technologies is also emerging as a key component of the company’s expansion strategy for PBP1510. Prestige Biopharma aims to establish a precision medicine platform that integrates diagnostics and therapeutics by leveraging the PAUF biomarker. The company is currently developing both tissue-based immunohistochemistry (IHC) diagnostic technologies and blood-based diagnostic approaches, while pursuing discussions with potential global partners with the goal of selecting a diagnostic kit partner within this year. These efforts are expected to maximize opportunities for patient selection, treatment response assessment, and future commercialization strategies associated with PBP1510.

Meanwhile, Prestige Biopharma emphasized that it maintains a stable financial foundation to support continued clinical and research & development activities across its key pipeline programs. The company noted that recent changes in earnings were primarily attributable to non-cash accounting expenses related to the recognition of impairment losses on investments in subsidiaries, rather than actual cash outflows. It also added that asset revaluations within its subsidiaries have further strengthened the company’s financial stability.

A company spokesperson stated, “Supported by strong cash reserves and disciplined financial management, we will continue to accelerate the clinical development of PBP1510, expand global partnering opportunities, and advance the commercialization strategy for PAUF-based diagnostic technologies.”

Source: The Korea Economic Daily(https://www.hankyung.com/article/202606019670i)